

Supplementary table 1

		Oligoarticular								
		Total (n 251)	ERA (n 22)	Extended (n 28)	Persistent (n 84)	RF- (n 35)	RF+ (n 17)	JPsA (n 17)	sJIA (n 7)	uJIA (n 41)
Glucocorticoids	No treatment	109 (43.4)	6 (27.3)	13 (46.4)	49 (58.3)	11 (31.4)	4 (23.5)	7 (41.2)	5 (71.4)	14 (34.1)
	NSAID	246 (98.0)	22 (100)	27 (96.4)	83 (98.8)	35 (100)	16 (94.1)	17 (100)	7 (100)	39 (95.1)
	Oral	107 (42.6)	11 (50)	14 (50)	12 (14.3)	21 (60)	14 (82.4)	7 (41.2)	5 (71.4)	23 (56.1)
	Oral < 2 months	65 (25.9)	8 (36.4)	12 (42.9)	11 (13.1)	14 (40)	8 (47.1)	2 (11.8)		10 (24.4)
	Intra-articular steroids	198 (78.9)	16 (72.7)	25 (89.3)	69 (82.1)	25 (71.4)	15 (88.2)	11 (64.7)	3 (42.9)	34 (82.9)
sDMARD	Methotrexate	152 (60.6)	15 (68.1)	23 (82.1)	27 (32.1)	32 (91.4)	17 (100)	11 (64.7)	2 (28.6)	25 (61.0)
	Salazopyrine	25 (10.0)	4 (18.2)	3 (10.7)	1 (1.2)	3 (8.6)	1 (5.9)	1 (5.9)		12 (29.3)
	Azathioprine	8 (3.2)	2 (9.1)	1 (3.6)		1 (2.9)	1 (5.9)			3 (7.3)
	Antimalarial drugs	17 (6.8)	1 (4.5)	6 (21.4)		2 (5.7)	2 (11.8)	1 (5.9)		5 (12.2)
bDMARD	TNFα-inhibitor	60 (23.9)	7 (31.8)	11 (39.2)	3 (3.6)	13 (37.1)	12 (70.5)	2 (11.8)	1 (14.3)	11 (26.8)
	TNFα-inhibitor + methotrexate	52 (20.7)	4 (18.2)	11 (39.2)	1 (1.2)	13 (37.1)	12 (70.6)	2 (11.8)	1 (14.3)	8 (19.5)
	Adalimumab	27 (10.8)	4 (18.2)	4 (14.3)	2 (2.4)	7 (20.0)	4 (23.5)	2 (11.8)		4 (9.8)
	Etanercept	44 (17.5)	3 (4.5)	11 (39.2)	2 (2.4)	7 (20.0)	9 (52.9)	2 (11.8)	1 (14.3)	9 (22.0)
	Infliximab	14 (5.6)	3 (4.5)			2 (5.7)	4 (23.5)	1 (5.9)	1 (14.3)	3 (7.3)
	Anakinra	2 (0.8)	1 (4.5)						1 (14.3)	
	Abatacept	3 (1.2)	2 (9.1)	1 (3.6)						
	Tocilizumab	7 (2.8)	2 (9.1)	2 (7.1)		1 (2.9)			1 (14.3)	1 (2.4)